125 related articles for article (PubMed ID: 30849059)
1. Drug-drug Interactions in Psychiatric Practice, Part 4: Classification of Neuropsychiatric Medications Based on Their Principal Mechanisms of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 Mar; 25(2):118-127. PubMed ID: 30849059
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 5: Major Types of Pharmacodynamic DDIs Based on Mechanism of Action (With Updated Neuroscience-based Nomenclature).
Preskorn SH; Germann A
J Psychiatr Pract; 2019 May; 25(3):206-211. PubMed ID: 31083033
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 2: Strategies to Minimize Adverse Outcomes From Unintended DDIs.
Preskorn SH
J Psychiatr Pract; 2018 Sep; 24(5):341-347. PubMed ID: 30427821
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 9: Interactions Mediated by Drug-metabolizing Cytochrome P450 Enzymes.
Preskorn SH
J Psychiatr Pract; 2020 Mar; 26(2):126-134. PubMed ID: 32134885
[TBL] [Abstract][Full Text] [Related]
5. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
Preskorn SH
J Psychiatr Pract; 2020 Jan; 26(1):46-51. PubMed ID: 31913969
[TBL] [Abstract][Full Text] [Related]
6. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 6: Pharmacodynamic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jul; 25(4):290-297. PubMed ID: 31291209
[TBL] [Abstract][Full Text] [Related]
7. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 7: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antipsychotics.
Preskorn SH
J Psychiatr Pract; 2019 Nov; 25(6):461-465. PubMed ID: 31821222
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug Interactions in Psychiatric Practice, Part 1: Reasons, Importance, and Strategies to Avoid and Recognize Them.
Preskorn SH
J Psychiatr Pract; 2018 Jul; 24(4):261-268. PubMed ID: 30427809
[TBL] [Abstract][Full Text] [Related]
9. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3: Pharmacokinetic Considerations.
Preskorn SH
J Psychiatr Pract; 2019 Jan; 25(1):34-40. PubMed ID: 30633730
[TBL] [Abstract][Full Text] [Related]
10. A new nomenclature for classifying psychotropic drugs.
Caraci F; Enna SJ; Zohar J; Racagni G; Zalsman G; van den Brink W; Kasper S; Koob GF; Pariante CM; Piazza PV; Yamada K; Spedding M; Drago F
Br J Clin Pharmacol; 2017 Aug; 83(8):1614-1616. PubMed ID: 28401576
[TBL] [Abstract][Full Text] [Related]
11. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.
Zohar J; Stahl S; Moller HJ; Blier P; Kupfer D; Yamawaki S; Uchida H; Spedding M; Goodwin GM; Nutt D
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2318-25. PubMed ID: 26527055
[TBL] [Abstract][Full Text] [Related]
12. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (part II).
Preskorn SH
J Psychiatr Pract; 2004 May; 10(3):177-81. PubMed ID: 15330224
[No Abstract] [Full Text] [Related]
13. Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications.
Möller HJ; Schmitt A; Falkai P
Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):385-6. PubMed ID: 27216433
[No Abstract] [Full Text] [Related]
14. Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update.
Spina E; Leon J
Curr Pharm Des; 2017; 23(37):5625-5638. PubMed ID: 28799514
[TBL] [Abstract][Full Text] [Related]
15. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
16. Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.
Wang Y; Bahar MA; Jansen AME; Kocks JWH; Alffenaar JC; Hak E; Wilffert B; Borgsteede SD
J Antimicrob Chemother; 2019 Oct; 74(10):2848-2864. PubMed ID: 31127283
[TBL] [Abstract][Full Text] [Related]
17. Potential drug-drug interactions among prescriptionsfor elderly patients in primary health care.
Gören Z; J Demirkapu M; Akpinar Acet G; Çali S; Gülçebi Idriz Oğlu M
Turk J Med Sci; 2017 Feb; 47(1):47-54. PubMed ID: 28263519
[TBL] [Abstract][Full Text] [Related]
18. Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next?
Uchida H
Psychiatry Clin Neurosci; 2018 Feb; 72(2):50-51. PubMed ID: 29436090
[No Abstract] [Full Text] [Related]
19. Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI.
Yap KY; Chui WK; Chan A;
Inform Health Soc Care; 2011 Sep; 36(3):132-46. PubMed ID: 21848450
[TBL] [Abstract][Full Text] [Related]
20. Countrywide prevalence of critical drug interactions in Hungarian outpatients: a retrospective analysis of pharmacy dispensing data.
Somogyi-Végh A; Ludányi Z; Erdős Á; Botz L
BMC Pharmacol Toxicol; 2019 May; 20(1):36. PubMed ID: 31151485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
